Multi-epitope DNA vaccines

Immunology and Cell Biology

Volumn 75, Issue 4, 1997, Pages 402-408

  Suhrbier, A ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Cytotoxic T lymphoeyte; DNA; EBV; Epitope; HIV; Melanoma; Polytope; Vaccine

Indexed keywords

ANTIBODY; CD4 ANTIGEN; DNA VACCINE; EPITOPE; EPSTEIN BARR VIRUS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MELANOMA VACCINE;

CANCER; DRUG DESIGN; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INFECTION; MELANOMA; NONHUMAN; REVIEW; T LYMPHOCYTE SUBPOPULATION; VACCINE PRODUCTION;

HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030885296     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1997.63     Document Type: Review

References (102)

1. Tam JP. Recent advances in multiple antigen peptides. J. Immunol. Methods 1996; 196: 17-32.
2. Ferru I, Georges B, Bossus M et al. Analysis of the immune response elicited by a multiple antigen peptide (MAP) composed of two distinct protective antigens derived from the parasite Schistosoma mansoni. Parasite Immunol. 1997; 19: 1-11.
3. O'Brien-Simpson NM, Ede NJ, Brown LE, Swan J, Jackson DC. Polymerization of unprotected synthetic peptides - a view toward synthetic peptide vaccines. J. Am. Chem. Soc. 1997; 119: 1183-8.
4. Jackson DC, O'Brien-Simpson NM, Ede NJ, Brown LE. Free radical induced polymerisation of synthetic peptides into polymeric immunogens. Vaccine 1997; (in press).
5. Laver WG, Air GM, Webster RG, Smith-Gill SJ. Epitopes on protein antigens: misconceptions and realities. Cell 1990; 61: 553-6.
6. Dreesman GR, Sanchez Y, Ionescu Matiu I et al. Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature 1982; 295: 158-60.
7. Steward MW, Stanley CM, Obeid OE. A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response. J. Virol. 1995; 69: 7668-73.
8. Brandt ER, Hayman WA, Currie B et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 1996; 89: 331-7.
9. Etlinger HM. Carrier sequence selection-one key to successful vaccines. Immunol. Today 1992; 13: 52-5.
10. Haynes BF, Moody MA, Heinley CS, Korber B, Millard WA, Scearce RM. HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen. AIDS Res. & Human Retroviruses 1995; 11: 211-21.
11. An LL, Whitton JL. A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vitro and confers protection against more than one pathogen. J. Virol. 1997; 71: 2292-302.
12. + cytotoxic T cells epitopes. J. Immunol. 1996; 157: 822-6.
13. Gueguen M, Long EO. Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long lived-form of the antigen. Proc. Natl Acad. Sci. USA 1996; 93: 14 692-7.
14. + cytotoxic T cells: Implications for vaccine design. Proc. Natl Acad. Sci. USA 1995; 92: 5845-9.
15. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with a polynucleotide vaccine. J. Infect. Dis. 1996; 173: 314-20.
16. Liu M, Donnelly J. Conference presentation. At 'Nucleic Acid Vaccines for the Prevention of Infectious Diseases'. NIH. Bethesda, USA Feb. 1996.
17. Sweetser MT, Morrison LA, Braciale VL, Braciale TJ. Recognition of pre-processed endogenous antigen by class I but not class II MHC-restricted T cells. Nature 1989; 342: 180-2.
18. Sanderson S, Frauwirth K, Shastri N. Expression of endogenous peptide major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc. Natl Acad. Sci. USA 1995; 92: 7217-21.
19. Wu TC, Guarnieri FG, Staveleyo'Carroll KF et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl Acad. Sci. USA 1995; 92: 11671-5.
20. Lin KY, Guarnieri FG, Staveleyocarroll KF et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996; 56: 21-6.
21. Parra-Lopez CA, Linder R, Vidavsky I, Gross M, Unanue ER. Presentation on class II MHC molecules of endogenous lysosome targeted to the endocytic pathway. J. Immunol. 1997; 158: 2670-9.
22. Wang Y, Smith JA, Gefter ML, Perkins DL. Immunodominance: Intermolecular competition between MHC class II molecules by covalently linked T cell epitopes. J. Immunol. 1992; 148: 3034-41.
23. Bhardwaj V, Kumar V, Geysen HM, Sercarz EE. Subjugation of dominant immunogenic determinants within a chimeric peptide. Eur. J. Immunol. 1992; 22: 2009-16.
24. +) T cells precedes the development of tolerance in vivo. Int. Immunol. 1996; 8: 335-42.
25. Tian JD, Atkinson MA, Claresalzler M et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces TH2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 1996; 183: 1561-7.
26. Groettrup M, Soza A, Kuckelkorn U, Kloetzel PM. Peptide antigen production by the proteasome - complexity provides efficiency. Immunol. Today 1996; 17: 429-35.
27. Hahn YS, Yang B, Braciale TJ. Regulation of antigen processing and presentation to class I MHC restricted CD8(+)T lymphocytes. Immunol. Rev. 1996; 151: 31-49.
28. Yellenshaw AJ, Eisenlohr LC. Regulation of class I-restricted epitope processing by local or distal flanking sequence. J. Immunol. 1997; 158: 1727-33.
29. Shastri N, Serwold T, Gonzalez F. Presentation of endogenous peptide MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. J. Immunol. 1995; 155: 4339-46.
30. Del-Val M, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 1991; 66: 1145-93.
31. Eggers M, Boesfabian B, Ruppert T, Kloetzel PM, Koszinowski UH. The cleavage preference of the proteasome governs the yield of antigenic peptide. J. Exp. Med. 1995; 182: 1865-70.
32. Niedermann G, Butz S, Ihlenfeldt HG et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 1995; 2: 289-95.
33. b-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen. J. Virol. 1995; 69: 3134-46.
34. Nomura M, Nakata Y, Inoue T et al. In vivo induction of cytotoxic T lymphocytes specific for a single epitope introduced into an unrelated molecule. J. Immunol. Methods 1996; 193: 41-9.
35. Weidt G, Deppert W, Buchhop S, Dralle H, Lehmanngrube F. Antiviral protective immunity induced by major histocompatibility complex class I molecule-restricted viral T-lymphocyte epitopes inserted in various positions in immunologically self and nonself proteins. J. Virol. 1995; 69: 2654-8.
36. Oldstone MB, Tishon A, Eddleston M, Delatorre JC, McKee T, Whitton JL. Vaccination to prevent persistent viral infection. J. Virol. 1993; 67: 4372-8.
37. Whitton JL, Sheng N, Oldstone MB, McKee TA. A 'string-of-beads' vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J. Virol. 1993; 67: 348-53.
38. McCabe BJ, Irvine KR, Nishimura MI et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res. 1995; 55: 1741-7.
39. Ciernik IF, Berzofsky JA, Carbone DP. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 1996; 156: 2369-75.
40. Sato Y, Roman M, Tighe H et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352-4.
41. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 1996; 184: 747-52 .
42. Layton GT, Harris SJ, Myhan J et al. Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology 1996; 87: 171-8.
43. +) cytotoxic T lymphocytes. Proc. Natl Acad. Sci. USA 1995; 92: 11 990-2.
44. Bouwer HGA, Hinrichs DJ. Cytotoxic-T-lymphocyte responses to epitopes of listeriolysin and P60 following infection with Listeria monocytogenes. Infect. Immun. 1996; 64: 2515-22.
45. Scalzo AA, Elliott SL, Cox J, Gardner J, Moss DJ, Suhrbier A. Induction of protective cytotoxic T cells to murine cytomegalovirus using a nonapeptide and a human compatible adjuvant (Montanide ISA 720). J. Virol. 1995; 69: 1306-9.
46. Ahmed R, Gray D. Immunological memory and protective immunity - understanding their relation. Science 1996; 272: 54-60.
47. Vitiello A, Ishioka G, Grey HM et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 1995; 95: 341-9.
48. Jager E, Ringhoffer M, Dienes HP et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 1996; 67: 54-62.
49. Gupta RK, Siber GR. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995; 13: 1263-76.
50. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high - or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci. USA 1996; 93: 4102-7.
51. Aichele P, Brduschariem K, Zinkernagel RM, Hengartner H, Pircher H. T cell priming versus T cell tolerance induced by synthetic peptides J. Exp. Med. 1995; 182: 261-6.
52. Moss D, Schmidt C, Elliott SL, Suhrbier A, Burrows S, Khanna R. Strategies involved in developing an effective vaccine to EBV-associated diseases. Adv. Can. Res. 1996; 69: 213-44.
53. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
54. Moss DJ, Suhrbier A. Epstein-Barr virus vaccines; prospects and limitations. Todays Life Science 1993; Sept: 30-4.
55. Hayashi K, Koirala TR, Ino H et al. Malignant lymphoma induction in rabbits by intravenous inoculation of Epstein-Bar virus-related herpesvirus from HTLV-II-transformed Cynomolgos leukocyte cell line (SI-IIA). Int. J. Cancer 1995; 63: 872-80.
56. Silins SL, Sculley TB. Burkitts lymphoma cells are resistant to programmed cell death in the presence of the Epstein-Barr virus latent antigen EBNA-4. Int. J. Cancer 1995; 60: 65-72.
57. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 1996; 15: 3117-26.
58. Khanna R, Burrows S, Kurilla M et al. Localisation of Epstein-Barr virus CTL epitopes in healthy immune donors using recombinant vaccinia: Implications for vaccine development. J. Exp. Med. 1992; 176: 169-76.
59. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 1996; 156: 238-45.
60. Marchand M, Weynants P, Rankin E et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 1995; 63: 883-5.
61. Kawakami Y, Eliyahu S, Delgado CH et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA 1994; 91: 6458-62.
62. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. New treatment options for patients with melanoma - review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res. 1996; 6: 11-24.
63. Boon T, van der Bruggen P. Human tumour antigens recognised by T lymphocytes. J. Exp. Med. 1996; 183: 725-7.
64. Hersey P. Melanoma peptides as vaccines. Todays Life Sciences 1996; April: 34-8.
65. Brasseur F, Rimoldi D, Lienard D et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer 1995; 63: 375-80.
66. Lehmann F, Marchand M, Hainaut P et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 1995; 25: 340-7.
67. Guilloux Y, Lucas S, Brichard et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the acetylglu-cosaminyltransferase V gene. J. Exp. Med. 1996; 183: 1173-83.
68. Tine JA, Lanar DE, Smith DM et al. Nyvac-PF7-apoxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 1996; 64: 3833-4.
69. Bellone M, Iezzi G, Manfredi AA et al. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur. J. Immunol. 1994; 24: 2691-8.
70. Luscher U, Filgueira L, Juretic A et al. The pattern of cytokine gene expression on freshly excised human metastatic melanoma suggest a a state of reversible anergy of tumor-infiltrating lymphocytes. Int. J. Cancer 1994; 57: 612-9.
71. + tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur. J. Immunol. 1994; 24: 1966-73.
72. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 1996; 274: 1363-6.
73. Ellem KAO, O'Rourke, MGE, Johnson, GJ et al. A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol. Immunother. 1997; 44: 10-20.
74. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Res. 1995; 55: 4941-9.
75. Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Endogenous IL-12 is necessary for rejection of p815 tumor variants in vivo. J. Immunol. 1996; 156: 1095-100.
76. Rowland-Jones SL, McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus. Curr. Opin. Immunol. 1995; 7: 448-55.
77. Gotch F, Gallimore A, Mcmichael A. Cytotoxic T cells - protection from disease progression - protection from infection. Immunol. Lett. 1996; 51: 125-8.
78. Premack BA, Schall TJ. Chemokine receptors; gateways to inflamation and infection. Nat. Med. 1996; 2: 1174-8.
79. Fauci AS. Resistence to HIV infection: It's in the genes. Nat. Med. 1996; 2: 966-7.
80. Clerici M, Shearer GM. Correlates of protection in HIV infection and the progression of HIV infection to AIDS. Immunol. Lett. 1996; 51: 69-73.
81. Borrow P, Lewicki H, Wei X et al. Antiviral pressure exerted by HIV-1-specific CTL during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 1997; 3: 205-11.
82. Goulder PJ, Phillips RE, Colbert RA et al. Late escape from an immunodominant CTL response associated with progression to AIDS. Nat. Med.1997; 3: 212-7.
83. Autran B, Hadida F, Haas G. Evolution and plasticity of CTL responses against HIV. Curr. Opin. Immunol. 1996; 8: 546-53.
84. Deacon NJ, Tsykin A, Solomon A et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270: 988-91.
85. Murphey-Corb M. Live-attenuated HIV vaccines: How safe is safe enough? Nat. Med. 1997; 3: 17-18.
86. DNA Vaccine Web; http://www.genweb.com/Dnavax/ dnavax.html
87. HIV Molecular Immunology Database; http://hiv-web. lanl.gov:80/immuno/about.html
88. Klenerman P, Phillips R, Mcmichael A. Cytotoxic T-cell antagonism in HIV-1. Seminars in Virology 1996; 7: 31-9.
89. Dalgleish AG. The immune response to HIV: Potential for immunotherapy. Immunol. Today 1995; 16: 356-8.
90. Zanussi S, Simonelli C, Dandrea M et al. CD8(+) Lymphocyte phenotype and cytokine production in long-term nonprogressor and in progresser patients with HIV-1 infection. Clin. Exp. Immunol. 1996; 105: 220-24.
91. Clerici M, Balotta C, Meroni L et al. Type I cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection. AIDS Res. & Human Retroviruses 1996; 12: 1053-61.
92. Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines co-expressed in recombinant fowlpox virus. J. Virol. 1994; 68: 8125-30.
93. Cohen, J. Chemokines share centre stage with drug therapies. Science 1996; 273: 302-3.
94. Adams D, Lloyd A. Chemokines; leucocyte recruitment and activation cytokines. Lancet 1997; 349: 490-5.
95. Levy JA, Mackewicz CE, Barker E. Controlling HIV pathogenesis - the role of the noncytotoxic anti-HIV response of CD8(+) T cells. Immunol. Today 1996; 17: 217-24.
96. Miller CJ, McGhee JR. Progress towards a vaccine to prevent sexual transmission of HIV. Nat. Med. 1996; 2: 751-2.
97. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med. 1996; 184: 1879-90.
98. Shearer GM, Clerici M. Rethinking AIDS and cancer. Science 1996; 274: 163-4.
99. Egan MA, Pavlat WA, Tartaglia J et al. Induction of HIV type 1 (HIV-1)-specific CTL responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1 MN env gene. J. Infect. Dis. 1995; 171: 1623-7.
100. Barnes J. Peptide based EBV vaccine in phase I trial. Inpharma Weekly (Adis Int. Inc.) 1995; 6th May. 985; 11-12.
101. Martin SJ, Vyakarnam A, Cheingsong-Popov R et al. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. AIDS 1993; 7: 1315-23.
102. Yasutomi Y, Robinson HL, Lu S et al. Simian immunodeficiency virus-specific CTL induction through DNA vaccination of rhesus monkeys. J. Virol. 1996; 70: 678-81.